Coronavirus: Commission proposes EU Strategy for the development and availability of therapeutics

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


The European Commission is today complementing the successful EU Vaccines Strategy with a strategy on COVID-19 therapeutics to support the development and availability of much-needed COVID-19 therapeutics, including for the treatment of ‘long COVID’. Today’s Strategy covers the full lifecycle of medicines: from research, development and manufacturing to procurement and deployment.

It is part of the strong European Health Union, in which all EU countries prepare and respond together to health crises and ensure the availability of affordable and innovative medical supplies – including the therapeutics needed to treat COVID-19.

The Strategy includes clear actions and targets, including authorising three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year. Concretely:

  • Research, development and innovation
    • Invest €90 million in population studies and clinical trials to establish links between risk factors and health outcomes to further inform public health policy and clinical management, including for long-COVID patients.
    • Set up a ‘therapeutics innovation booster’ by July 2021 to support the most promising therapeutics from preclinical research to market authorisation. It will build on current initiatives and investments in therapeutic development, working in a close cooperation with the European Health Emergency Preparedness and Response Authority (HERA) preparatory action on mapping therapeutics. It will therefore ensure the coordination of all research projects on COVID-19 therapeutics, stimulating innovation and boosting therapeutic development.
  • Access to and swift approval of clinical trials
    • Invest €5 million under the EU4Health programme to generate better, high-quality safety data in clinical trials, which will help produce robust results in a timely manner.
    • Provide EU countries with financial support of €2 million under the EU4Health 2021 work programme for expedited and coordinated assessments to facilitate approval of clinical trials.
    • Explore how to support developers of therapeutics to build capacity to produce high-grade material for clinical trials.
  • Scanning for candidate therapeutics
    • Invest €5 million to map therapeutics and diagnostics to analyse development phases, production capacities and supply chains, including possible bottlenecks.
    • Establish a broader portfolio of 10 potential COVID-19 therapeutics and identify five of the most promising ones by June 2021.
  • Supply chains and delivery of medicines
    • Fund a €40 million preparatory action to support flexible manufacturing and access for COVID-19 therapeutics under the EU Fab project, which in turn will become over time an important asset for the future the European Health Emergency Preparedness and Response Authority (HERA).
  • Regulatory flexibility
    • Authorise at least three new therapeutics by October and possibly two more by the end of the year and develop flexible regulatory approaches to speed up the assessment of promising and safe COVID-19 therapeutics.
    • Start seven rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes.
  • Joint procurement and financing
    • Launch new contracts for the purchase of authorised therapeutics by the end of the year.
    • Secure faster access to medicines with shorter administrative deadlines.
  • International cooperation to make medicines available to all
    • Reinforce engagement for the therapeutics pillar of the Access to COVID-19 Tools Accelerator.
    • Boost ‘OPEN’ initiative for international collaboration.

Next Steps

The Commission will draw up a portfolio of 10 potential COVID-19 therapeutics and by June 2021, identify the five most promising ones. It will organise matchmaking events for industrial actors involved in therapeutics to ensure enough production capacity and swift manufacturing. New authorisations, rolling reviews and joint procurement contracts will be up and running before the end of the year.

The therapeutics innovation booster, matchmaking events and preparatory action to support flexible manufacturing and access for COVID-19 therapeutics under the EU Fab project, will feed into the HERA, for which a proposal is due later in the year. The pilot project on access to health data will feed into the European Health Data Space proposal expected later this year.

Members of the College said:

Vice-President for Promoting our European Way of Life, Margaritis Schinas, said: The situation in many intensive care units across the continent remains critical. We need to focus both on vaccines and therapeutics, as two powerful and complementary ways to combat COVID-19. But currently we have only one authorised medicine to treat COVID-19. By acting on better availability of medicines today, we are making sure patients receive the treatments they need while also preparing our future biomedical preparedness. A coordinated strategy on quick access to therapeutics will boost our strategic autonomy and contribute to a strong Health Union.”

Commissioner for Health and Food Safety, Stella Kyriakides, said:“Vaccinations save lives, but they cannot yet eradicate COVID-19. We need a strong push on treatments to limit the need for hospitalisation, speed up recovery times, and reduce mortality. Patients in Europe and across the world should have access to world-class COVID-19 medicines. This is why we have set a very clear goal: by October, we will develop and authorise three new effective COVID-19 therapeutics that can have the potential to change the course of the disease. We will do so by investing in research and innovation, the identification of new promising medicines, ramping up production capacity and supporting equitable access. Our Therapeutics Strategy is a strong European Health Union in action.”

Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, said: “By increasing vaccine availability across Europe, more and more Europeans are now protected against COVID-19. In the meantime, the development of innovative medicines to treat coronavirus patients remains a priority when it comes to saving lives. Research and innovation is the first step to finding effective and safe therapeutics, which is why we are proposing to establish a new COVID-19 ‘therapeutics innovation booster’ and will invest € 90 million in population studies and clinical trials.

Background

The Strategy on COVID-19 therapeutics complements the EU strategy for COVID-19 vaccines from June 2020 and builds on ongoing work by the European Medicines Agency and the Commission to support research, development, manufacturing and deployment of therapeutics.

The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve the resilience of Europe’s health systems.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

This farmer used an age-old technique to save his soil and now his farm is prospering

Stronger partnerships with post-conflict countries needed to ensure ‘path towards durable peace’: UN chief

EU consumer rules: Airbnb cooperates with European Commission and EU consumer authorities improving the way it presents offers

Assembly President launches new initiative to purge plastics and purify oceans

To feed 10 billion people, we must preserve biodiversity. Here’s how

Fragile countries risk being ‘stuck in a cycle of conflict and climate disaster,’ Security Council told

State aid: Commission approves €1.4 billion Swedish scheme to support uncovered fixed costs of companies affected by coronavirus outbreak

Women’s rights: MEPs call for action to fight backlash against gender equality

Tax crimes: MEPs want EU financial police force and financial intelligence unit

Reusable packaging: 6 benefits beyond sustainability

Our present and future tax payments usurped by banks

Aviation Safety: Commission adopts new EU Air Safety List

This is how COVID-19 is affecting informal workers

Eurozone stagnates after exporting its recession to trading partners

Juncker Plan reaches almost €410 billion in triggered investment across the EU

Technology can transform clinical practice – here’s how

Knowledge management and entrepreneurship: short term vs. long term perspective

The Cold War had an unintended side effect: It created a European wildlife paradise

‘Counter and reject’ leaders who seek to ‘exploit differences’ between us, urges Guterres at historic mosque in Cairo

MWC 2016 LIVE: Xiaomi looks to revive growth with flagships

How our food system is eating away at nature, and our future

Medical workforce migration in Europe – Is it really a problem?

Four things workers want implemented by their bosses post-pandemic

‘Unlock opportunities’ and pave the way for sustainable development, UN chief urges on World Population Day

This Japanese experiment shows how easily coronavirus can spread – and what you can do about it

EU and Georgia sign Financing Agreements for COVID-19 Recovery worth €129 million

Security Council urges countries to factor child protection into conflict prevention efforts

Peer-to-peer learning: a way to develop medical students’ trainings

The Fourth Industrial Revolution is driving Globalization 4.0

MEPs demand safe and clean travel

3 ways to stop COVID-19 from drying up start-up talent pools

European Business Summit 2015: In search of a vision for the future

Apple® logo (copyright: Apple)

Apple takes further step into music: EU Regulators formally approve its planned Shazam acquisition

How do we upskill a billion people by 2025? Leadership and collaboration will be key

Palliative care: an indispensable component for a better quality of life

Idea of ‘homogenous’ Polish culture is a myth: UN human rights expert

Unity, regional cooperation and international support needed for Horn of Africa to develop sustainably

How we can work together in the fight against NCDs

The first-ever climate telethon has raised $2.6 million for new forests

Parliament approves seven-year EU budget 2021-2027

Anti-terror measures against youngsters’ online posts ‘linked to spike in child detention globally’

Hiring more female leaders is good for profits. Here’s the evidence

More than nine in ten children exposed to deadly air pollution

How the world’s best teacher is changing lives in Africa

Coronavirus: Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

Mindfulness: a freedom we can still have in the pandemic

Obama turns the G20 summit into warmongering platform

Cheese energy could power hundreds of UK homes

COVID-19: MEPs fear impact on justice system and threat to rule of law

Greek citizens to pay the price again but Tsipras risks losing next elections

5 lessons for community-focused planning during a pandemic

The challenge to be a good healthcare professional

Mental health In Times of a Pandemic: What can each Individual to lessen the Burden.

WHO and UNICEF in campaign to protect 1.6 million in Sudan from cholera

UN ready to rise above political fray and help Venezuelans based ‘on need, and need alone’

Commission notifies the Republic of Panama over the need to step up action to fight against illegal fishing

This man is helping explorers carry out scientific research at the ends of the Earth

CLIMATE CHANGE FOCUS: Cows, coffee and sustainable farming

“Smoking steam instead of tobacco, are the E-cigarettes a safer alternative?”

Wages are flatlining around the world – is automation to blame?

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s